ProKidney Corp. reported encouraging Phase II trial results for its cell therapy rilparencel in chronic kidney disease patients, showing a 78% slowing of kidney function decline in the two-dose cohort, deemed statistically and clinically significant. However, the single-dose group did not achieve statistically meaningful benefits. The company is seeking FDA guidance to use eGFR slope as a surrogate endpoint in its ongoing Phase III study. The therapy leverages autologous progenitor cells formulated for kidney injection to support damaged tissue repair. The mixed outcome highlights potential dose dependence and supports continued development of the treatment to address CKD progression in diabetic patients.